NovImmune SA secured CHF62.5 million (US$56.5 million) in what may well turn out to be the largest private equity deal completed by a European biotechnology firm this year. (BioWorld Today)
No Abstract BioWorld International CorrespondentProtAffin AG raised €14 million (US$18.3 million) in a Series B round to progress its early stage pipeline of novel, protein-based therapeutics that act by disrupting biological signaling between extracellular glycan structures and their protein ligands.The Graz, Austria-based company is adding 11 new staff on the strength of the new funding, boosting total headcount to 27 people.
Evotec AG's near-term partnering options narrowed on news that its smoking cessation drug EVT 302 failed to demonstrate efficacy in a Phase II proof-of-concept trial involving 414 smokers. (BioWorld International)
